
CytoSorbents (CTSO) Stock Forecast & Price Target
CytoSorbents (CTSO) Analyst Ratings
Bulls say
CytoSorbents is expected to continue its positive growth trend as they have had stable quarterly revenue and modest full-year growth, with a focus on improving gross margins through increased efficiency and continued regulatory progress for their key product DrugSorb-ATR. Management's approach of prioritizing process clarity over speed should reduce the risk of further regulatory hurdles and maintain a strong outlook for the company. With a strong focus on improving key applications of their proprietary blood purification technologies, CytoSorbents is poised for continued success in the USA, Germany, and other markets.
Bears say
CytoSorbents is facing declining sales in their core market in Germany, and while they attribute this to restructuring, there is no guarantee of sustained stabilization. Additionally, the company's cash balance of $7.8M highlights the need for successful execution of cost reduction and inventory normalization in order to reach their stated objective of a break even point in the second half of the year. The company's reliance on international sales to support growth and diversify their revenue stream also presents a risk in the face of potential economic and political disruptions.
This aggregate rating is based on analysts' research of CytoSorbents and is not a guaranteed prediction by Public.com or investment advice.
CytoSorbents (CTSO) Analyst Forecast & Price Prediction
Start investing in CytoSorbents (CTSO)
Order type
Buy in
Order amount
Est. shares
0 shares